30th May 2006 11:07
Stem Cell Sciences plc30 May 2006 Immediate Release 30th May 2006 Stem Cell Sciences PLC RESULT OF AGM At the Annual General Meeting held on 30.5.06 all the resolutions containedwithin the Notice of Meeting were passed. Two copies of the resolutions passed as special business at the AGM have beensubmitted to the UK Listing Authority and will shortly be available forinspection at the UK Listing Authority's Document Viewing Facility, which issituated at Financial Services Authority, 25 The North Colonnade, Canary Wharf,London, E14 5HS. -ENDS- For further information please contact: Stem Cell Sciences plc 0131 662 9829Peter Mountford Weber Shandwick | Square Mile 020 7067 2587James White Notes to Editors: Notes to Editors Stem Cell Sciences plc (SCS) is a global biotechnology company focused on thedevelopment of stem cell technologies. The Company has established a leadingintellectual property (IP) and technology portfolio that enables the commercialapplication of stem cells in pharmaceutical and biotechnology drug discovery,providing the Company with an early-stage revenue stream. In the longer term,the Company is developing regenerative, cell-based therapies. Stem Cell Sciences has four business units focused on key sustainable businessstrategies. SC Proven provides serum free, cell culture media (liquid formulations) andreagents that enable the growth and differentiation of stem cells for basicresearch and drug discovery purposes. The first commercially available product,a mouse embryonic stem cell growth medium, has been exclusively licensed formanufacture and marketing to Chemicon, a division of Serologicals Inc.SC Licensing licenses SCS proprietary technologies, such as Internal RibosomeEntry Site (IRES) and Stem Cell Selection, for application in laboratory-basedresearch and discovery. Current licenses for IRES are in place with Deltagen Incand Lexicon Genetics Inc. SC Services will provide specialised stem cell production for basic research anddrug discovery, including high-throughput applications.SC Therapies goal is to develop safe and effective cell-based therapies forcurrently incurable diseases. The first programme is being undertaken by SCS'Japanese affiliate, which recently announced the exclusive licensing of humanmultipotent tissue stem cells (hMADS) for therapeutic purposes. SCS KK plans toconduct initial preclinical studies to evaluate their potential application inthe treatment of Duchene's Muscular Dystrophy. SCS plc is a global Company with operations in the UK, Australia, and via itsassociate company in Japan. Each company is affiliated with a regional centre ofacademic excellence facilitating the global commercialisation of new IP and celllines. These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK,RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem CellCentre, Melbourne, Australia. SCS, which listed on the London Alternative Investment Market in July 2005, wasfounded in 1994 to commercialise findings from the ISCR and Monash University,Melbourne, Australia. The Company is a participant in two research projectsunder the European Union's Framework Six Programme for Research and TechnologyDevelopment and is a contributor to the UK Stem Cell Initiative. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree